Rikke Rytter - Genovis AB VP Marketing

GENO Stock

SEK 28.05 0.85 3.13%

Insider

Rikke Rytter is VP Marketing of Genovis AB

Age	56
Phone	46 46 10 12 30
Web	https://www.genovis.com

Genovis AB Management Efficiency

The company has return on total asset (ROA) of 0.1453 % which means that it generated a profit of $0.1453 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3659 %, meaning that it generated $0.3659 on every $100 dollars invested by stockholders. Genovis AB's management efficiency ratios could be used to measure how well Genovis AB manages its routine affairs as well as how well it operates its assets and liabilities.

Compare Genovis AB to Peers

Predict price of Genovis AB

Genovis AB has accumulated 1.12 M in total debt with debt to equity ratio (D/E) of 10.6, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Genovis AB has a current ratio of 3.16, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Genovis AB until it has trouble settling it off, either with new capital or with free cash flow. So, Genovis AB's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Genovis AB sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Genovis to invest in growth at high rates of return. When we think about Genovis AB's use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives			INSIDER Age
	Russell Thirsk	Bavarian Nordic	N/A
	Gry Larsen	BioPorto	N/A
	Niels Kristensen	cBrain AS	N/A
	Rolf Srensen	Bavarian Nordic	N/A
	Henrik MSc	Bavarian Nordic	58
	Lars Uttenthal	BioPorto	N/A
	Anu Kerns	Bavarian Nordic	51
	Christopher Bird	BioPorto	N/A
	Nis Kruse	BioPorto	N/A
	Paul MSc	Bavarian Nordic	56
	Laurence Moerlooze	Bavarian Nordic	59
	Anthony Pare	BioPorto	60
	JeanChristophe May	Bavarian Nordic	56
	Neil CPA	BioPorto	55
	Ejvindgensen	cBrain AS	N/A
	Jennifer Zonderman	BioPorto	N/A
	Tony Summerlin	cBrain AS	N/A

Genovis AB develops, produces, and sells tools for developing new medications and diagnostics for customers in the medical device and pharmaceutical industries. Genovis AB was founded in 1999 and is based in Lund, Sweden. Genovis AB operates under Biotechnology classification in Sweden and is traded on Stockholm Stock Exchange. It employs 20 people. Genovis AB (GENO) is traded on Stockholm Exchange in Sweden and employs 37 people.

Management Performance

	Return On Equity	0.37
	Return On Asset	0.15

Genovis AB Leadership Team

Elected by the shareholders, the Genovis AB's board of directors comprises two types of representatives: Genovis AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genovis. The board's role is to monitor Genovis AB's management team and ensure that shareholders' interests are well served. Genovis AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genovis AB's outside directors are responsible for providing unbiased perspectives on the board's policies.

	Susanne Ahlberg, G Counsel
	BA BA, Pres Inc
	Magnus Langberg, Group Officer
	Maria Edholm, Controller
	Fredrik Olsson, Pres CEO
	Linda Andersson, VP Production
	Rikke Rytter, VP Marketing

Genovis Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Genovis AB a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

	Return On Equity	0.37
	Return On Asset	0.15
	Profit Margin	0.34 %
	Operating Margin	0.26 %
	Current Valuation	3.25 B
	Shares Outstanding	65.47 M
	Shares Owned By Insiders	23.86 %
	Shares Owned By Institutions	45.20 %
	Price To Earning	976.19 X
	Price To Book	25.09 X

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Genovis Stock Analysis

When running Genovis AB's price analysis, check to measure Genovis AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genovis AB is operating at the current time. Most of Genovis AB's value examination focuses on studying past and present price action to predict the probability of Genovis AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genovis AB's price. Additionally, you may evaluate how the addition of Genovis AB to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC